<DOC>
	<DOCNO>NCT03001323</DOCNO>
	<brief_summary>Given longer half life insulin degludec compare glargine /levemir , investigator believe insulin degludec reduce rate recurrent DKA . The investigator randomize participant control intervention group . Control group receive Lantus/Levemir intervention group receive degludec . The investigator call participant monthly see clinic every three months.The investigator follow 1 year evaluate difference rate DKA two group .</brief_summary>
	<brief_title>Insulin Degludec Management Patient With Recurrent Diabetic Ketoacidosis</brief_title>
	<detailed_description>Hypothesis : Use longer-lasting basal insulin ( degludec ) patient recurrent Diabetic Ketoacidosis ( DKA ) reduce rate recurrent DKA improve adherence daily administration patient 2 episode DKA past 2 year . STUDY DESIGN AND METHODS : Patients admit Diabetic Ketoacidosis ( DKA ) Hennepin County Medical Center ( HCMC ) prior episode DKA within 2 year offer enrollment prospective , randomize unblinded trial determine whether long act insulin degludec reduce rate recurrent DKA improve compliance period 1 year compare control group stay pre-study long act insulin ( glargine detemir ) . Primary Outcomes : To determine difference rate recurrent Diabetic Ketoacidosis ( DKA ) 6 month 12 month participant history previous DKA medication adherence group treat degludec vs long-acting insulin ( glargine detemir ) . Secondary outcome : BG control ( Hba1c study period ) test q 3 month Discharge long-acting insulin dose compare admission dose LOS DKA admission Number readmission one year Number ER visit Hypoglycemia -self report , document glucometer ER visit severe hypoglycemia Adherence study regimen phone call information clinic visit Inclusion criterion : Patients age &gt; 18 year previous diagnosis Diabetes Mellitus previous admission DKA facility within prior 2 year meet criterion DKA time admission willing participate study protocol enrol study . DKA define : 1 . Serum bicarbonate 18 mg/dl 2 . Anion Gap great equal 16 3 . Serum ketones beta hydroxybutyrate elevation &gt; 3 mmol/L 4 . Serum glucose great equal 250 mg/dl Exclusion Criteria : Patients previous DKA , patient willing consent participate study protocol 1 year , pregnant woman , dementia , end stage renal disease dialysis . Study Protocol : Investigators obtain informed consent enroll participant admit Hennepin County Medical Center ( HCMC ) study Jan 2016 investigator adequate enrollment . Investigators collect initial data follow : 1 . Age , sex , height , weight , BMI 2 . Age diagnosis diabetes 3 . Number previous DKA admission past 2 year , lifetime ( even admission hospital ) 4 . Preadmission insulin dose - long act 5 . Reason DKA 6 . Alcohol , drug use , homelessness , mental illness 7 . Admission lab - HCO3 , AG , BOHB , glucose , creatinine 8 . Length stay DKA episode ( LOS ) The participant randomly assign intervention control group . Intervention Group : Discharge day degludec insulin pen ( supplied Novo ) dose 0.3 U/kg reduction 0.2 U/kg GFR &lt; 30 ml/hr . Degludec insulin start study initiation hospitalization participant randomize arm . Fast act insulin participant use adjust total daily dose give cover 2 3 meal equal long-acting insulin dose . Participants basal bolus regimen either use carbohydrate counting set dos meal , depend ability . Participants use fast act insulin time admission . Insulin adjustment hypoglycemia ( le 60 mg/dl ) fast BG 140 despite insulin compliance . For hypoglycemia , dose lower 0.05 U/kg elevate fast glucose raise 0.05 U/kg . Phone call every month check dose , compliance , hospital admission , hypoglycemia . Compliance medication verify verbally . Clinic visit every 3 month 1 year dose adjustment . Supply adequate insulin degludec next visit . Control Group : Discharge 0.3 U/kg admission long act insulin glargine detemir ( provide diabetes endocrine clinic ) regardless participant 's home insulin regimen time admission reduction 0.2 U/kg CKD GFR &lt; 30 ml/hr . This do time study initiation hospitalization participant randomize arm . Fast act insulin adjustment meal insulin adjustment hypoglycemia do similarly intervention group . Phone call every month check dose , compliance , hospital admission , hypoglycemia . Compliance assess verbally . Clinic visit every 3 month 1 year insulin dose adjustment . Supply adequate insulin glargine detemir next visit . Study site : Hennepin County Medical Center ( HCMC ) , Minneapolis , MN . Data Analysis : Sample size , power calculation statistical plan Investigators determine consider incidence DKA 100 % ( since patient admit DKA would eligible screen ) , moreover , order observe 30 % reduction DKA relate hospitalization 2 year period intervention group keep power 80 % confidence interval ( CI ) 0.05 , study need enroll 21 subject group 42 total sample size . In order mitigate effect loss follow , noncompliance protocol deviation , intention treat ( ITT ) analysis perform primary secondary outcome measure group . A separate analysis do include patient complete trial group . Baseline data intervention control group compare . In case significant difference , analysis do adjust difference prior final analysis . ITT analysis base ITT comparison . Descriptive inferential statistical method use analyze data use Statistical Analysis software ( SAS ) 9.4 . For continuous variable , mean , median variance report , discrete variable rate , risk ratio , relative risk , rate occurrence percentage difference report . For primary outcome measure , investigator use Ï‡2 test ass relationship primary outcome binary nature secondary measure . Stratification use analysis need . In case , chi-square test overall within relevant stratification conduct . To assess difference continuous variable ( hemoglobin A1C , bicarbonate , anion gap , Creatinine etc . ) , t-test use normally distribute data . Otherwise Mann-Whitney U test use . P-values 95 % CI report . Since superiority trial , use one-tail test significance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Ketosis</mesh_term>
	<mesh_term>Diabetic Ketoacidosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Patients age &gt; 18 year previous diagnosis Diabetes Mellitus previous admission DKA facility within prior 2 year meet criterion DKA time admission willing participate study protocol enrol study . DKA define : 1 . Serum bicarbonate 18 mg/dl 2 . Anion Gap great equal 16 3 . Serum ketones beta hydroxybutyrate elevation &gt; 3 mmol/L 4 . Serum glucose great equal 250 mg/dl Patients previous DKA , patient willing consent participate study protocol 1 year , pregnant woman , dementia , end stage renal disease dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>